Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Momelotinib treatment

Phase 2Small molecule

GGroupe Francophone des Myelodysplasies

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

VEXAS SyndomeRecruiting

VEXAS SyndomePhase 2

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

VEXAS Syndome

NCT07098936

Clinical

Trials by Indication[1]

VEXAS Syndome1 trial

A Single-arm Phase II With safety-run-in Multicenter Study of Momelotinib in Patients With VEXAS Syndrome With or Without Associated Myelodysplastic Syndrome

Recruiting·GGroupe Francophone des Myelodysplasies·Phase 2·NCT07098936·57 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Momelotinib treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Momelotinib treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Momelotinib treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Groupe Francophone des Myelodysplasies company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGroupe Francophone des Myelodysplasies

Related News